Home
Insights
Bexson Biomedical logo

Bexson Biomedical

1 Follower

Wires

Team announcement

Dr. Noah Craft Joins Bexson Biomedical as an Advisor

Dr. Noah Craft Joins Bexson Biomedical as an Advisor

Bexson Biomedical, a research stage company developing a proprietary ketamine-based subcutaneous treatment platform for pain management and mental health disorders, has announced that Noah Craft, MD, PhD has joined the company as an advisor. Dr. Craft will provide perspective to Bexson's R&D program and guidance for its novel ketamine delivery platform. Dr. Craft has held leadership roles at several healthcare R&D companies, and has served on multiple corporate boards. He recently co-founded and served as CEO and Board Director of a transformative technology-enabled clinical research company, called Science 37. Earlier in his career, he was a translational research scientist at the Lundquist Institute and UCLA. In a press release, Dr. Craft said, "This is a critical time for our society to be developing better therapies for both pain and mental health conditions. Bexson's ketamine-based therapy for these diseases is first of its kind. As we accelerate this R&D pipeline, we will continue to innovate with a patient-centered approach." Bexson Biomedical CEO Gregg Peterson said, “Dr. Craft's innovations in clinical trial design helped launch an industry-wide transformation that is making clinical research better for patients.”

Team announcement

Bexson Biomedical Adds Dr. Bill Carson as an Advisor

Bexson Biomedical Adds Dr. Bill Carson as an Advisor

Bexson Biomedical, a research stage company developing a proprietary ketamine-based subcutaneous treatment platform for pain management and mental health disorders, announced the addition of Bill Carson, MD as an advisor to the company. In his position, Dr. Carson will provide perspective to Bexson's R&D program and guidance for its novel ketamine delivery platform. Dr. Carson is an internationally recognized pharmaceutical and biotechnology leader, and has guided the global approval of several drugs and digital medicines. He is currently the Chairman of the Board, and the former President & CEO of Otsuka Pharmaceutical Development & Commercialization. In a press release, Bexson Biomedical CEO Gregg Peterson said, “Dr. Carson's many FDA approvals and commercial success while leading Otsuka illustrate his ability to optimize technology in our highly regulated industry." Dr. Carson stated, "I am encouraged by Bexson's R&D programs and hopeful that the company's technologic innovations will provide better treatment options for opioid-dependent patients."

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.